The Developmental Research Program is an important component of the SPORE and critical to the long-term fight against cervical cancer. It provides an avenue for soliciting new research ideas and for developing innovative high-risk, but high-impact projects to stimulate cervical cancer research in the context of the SPORE. Pilot studies provide investigators with the resources to conduct translational research consistent with the SPORE?s objectives. This program continues to encourage participation from a broad range of investigators at Johns Hopkins University (JHU), University of Colorado at Boulder (UCB), Mount Sinai Icahn School of Medicine (MSSM) and University of Alabama at Birmingham (UAB) by providing support for pilot projects with the potential to develop into more fully developed translational projects. It also encourages and facilitates the development of new research directions, methodologies, and collaborations. In addition, the JHU Sidney Kimmel Comprehensive Cancer Center also provides $75,000 annually as match funds for the Developmental Research Program. UAB will also contribute $40,000 annually to be used in the Career Development or Developmental Research program.
Specific Aims 1) Provide initiating funds for novel explorations related to cervical cancer. 2) Integrate the awardee into the SPORE community by participation in monthly meetings, group communications, and opportunities for expanded funding and for collaborations 3) Review progress and recommend avenues for continuation of successful projects

Public Health Relevance

The DRP is an important mechanism for nurturing new ideas and techniques relevant to cervical cancer to reach the level of full projects in the SPORE, and attracting new faculty members to work on cervical cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Sinno, A K; Li, X; Thompson, R E et al. (2017) Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care. Gynecol Oncol 145:493-499
Stewart, Katherine Ikard; Fader, Amanda N (2017) New Developments in Minimally Invasive Gynecologic Oncology Surgery. Clin Obstet Gynecol 60:330-348
Jiang, Rosie T; Wang, Joshua W; Peng, Shiwen et al. (2017) Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection. J Virol 91:
Yoo, Wonsuk; Kim, Sangmi; Huh, Warner K et al. (2017) Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One 12:e0172548
Moukarzel, Lea A; Angarita, Ana M; VandenBussche, Christopher et al. (2017) Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. J Low Genit Tract Dis 21:91-96
Huh, Warner K; Guido, Richard (2017) Transitioning from HPV 101 to HPV 202. Am J Obstet Gynecol 216:206-207
Yang, Pei-Ming; Chou, Chia-Jung; Tseng, Ssu-Hsueh et al. (2017) Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget 8:46145-46162
Fader, Amanda N (2017) Minimally Invasive Techniques for Treating Gynecologic Malignancies. J Natl Compr Canc Netw 15:730-732
Mehta, Ambar; Xu, Tim; Hutfless, Susan et al. (2017) Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications. Am J Obstet Gynecol 216:497.e1-497.e10
Yang, Andrew; Farmer, Emily; Lin, John et al. (2017) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res 231:148-165

Showing the most recent 10 out of 273 publications